Deltex Med Grp PLC DEMG NHS South Innovation Plan

  Deltex Med Grp PLC (DEMG) - NHS South Innovation Plan

RNS Number : 2648P
Deltex Medical Group PLC
23 October 2012



                           Deltex Medical Group plc


             Details published of NHS South plan to implement ODM

23 October 2012 - Deltex Medical  Group plc, the global leader in  oesophageal 
Doppler monitoring ("ODM"), notes that NHS South of England has published  its 
"Innovation Health and Wealth: Innovation Plan" which includes targets for the
implementation of national high impact innovations.

The plan  sets out  local targets  for CQUIN  (Commissioning for  Quality  and 
Innovation) incentive payments  for each  of the six  high impact  innovations 
specified in  December 2011's  Innovation: Health  and Wealth  report, one  of 
which was  to  launch  a  drive  to implement  fully  "ODM  or  similar  fluid 
management monitoring technologies" across the NHS.

The NHS South of England targets  for fluid management are expressed in  terms 
of numbers  of patients  a year  treated  per 100,000  of population  and  the 
targets set are:

· 150 patients per 100,000 in February and March 2013

· 200 patients  per 100,000 in  the NHS financial  year starting  1April 

· 250 patients  per 100,000 in  the NHS financial  year starting 1  April 

· 400 patients  per 100,000 in  the NHS financial  year starting 1  April 

In the year  ended 31December 2011,  CardioQ-ODM was used  during surgery  on 
circa 50 patients a year per 100,000 of population in NHS South of England and
the Directors of Deltex  Medical believe that CardioQ-ODM  is by some way  the 
market leading fluid management monitor in surgery in the region.

NHS South  of England  covers a  population of  over 13million,  just over  a 
quarter of  the  population of  England.  It estimates  that  53,789  surgical 
patients would be treated  with intra-operative fluid management  technologies 
in 2015/16 in the South of England, approximately 25% of the 220,000 who would
be treated with 100% compliance with  the NICE (National Institute for  Health 
and Clinical Excellence) guidance on CardioQ-ODM.

The plan notes that its regional targets for adoption of intra-operative fluid
management  may  "be  updated  following   completion  of  national  work   on 
pre-qualification requirements for CQUIN".

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"Successful implementation of the NHS South of England plan will cause a  step 
change in the market  for intra-operative fluid  management monitoring in  the 
region in the  next two  and a  half years,  with clear  potential for  either 
faster or further growth to  address the remaining three-quarters of  patients 
where NICE already recommend CardioQ-ODM usage.

"CardioQ-ODM has a strong market leadership  position in the NHS, is the  most 
widely  applicable  technology  available  for  major  surgery,  is  the  only 
technology recommended by  NICE and is  the only technology  with an  evidence 
base that shows  both improved outcomes  for patients and  reduced lengths  of 
hospital stay which are the benefits being pursued by the NHS."

For further information, please contact:-

Deltex Medical Group plc 01243 774 837

Nigel Keen, Chairman

Ewan Phillips, Chief Executive

Paul       Mitchell,        Finance        Director

Nominated Adviser & Broker

Arden Partners plc 020 7614 5900

Chris Hardie

Kreab Gavin Anderson 020 7074 1800

Robert              Speed

Deborah               Walter

Notes for Editors

Deltex Medical manufactures and  markets the CardioQ-ODMÔ system.  CardioQ-ODM 
changes the way doctors  care for surgical patients  allowing them to  recover 
faster and leave  hospital sooner  and in  better health  than they  otherwise 
would  do.  The  performance  of   the  system  has  been  validated   through 
independently conducted, randomised  controlled clinical trials  and is  being 
translated into  routine clinical  practice in  leading hospitals  around  the 

CardioQ-ODM comprises a monitor and a single patient disposable probe. The
probe is placed into the oesophagus through either the mouth or nose and the
tip positioned facing the adjacent descending aorta. A low frequency
ultrasound signal, generated by the monitor, is bounced off the blood
travelling down the aorta and the Doppler principle is used to determine the
velocity of the blood flow, expressed in distance per cardiac cycle - 'Stroke
Distance'. The monitor also calculates the amount of time that blood is
flowing down the aorta as a proportion of a cardiac cycle - 'Flow Time'.

The monitor uses a validated proprietary nomogram to extrapolate volumetric
data (Stroke Volume, Cardiac Output etc) from the directly measured flow
velocity. The nomogram utilises the patient's age weight and height,
effectively to estimate the size of the aorta in which the velocity of the
flow is being measured. Crucially this means that any reported relative change
in Stroke Volume is absolutely identical to the relative change in the
directly measured flow velocity variable of Stroke Distance. CardioQ-ODM
immediately and reliably identifies even very small changes in the blood flow
velocity allowing doctors to intevene earlier and on smaller changes than with
any other approach.

Intra-operative individualised Doppler guided fluid management entails
insertion and focusing of the probe to obtain a baseline reading, giving a
small (200 to 250 ml) fluid challenge directly into the vascular system and
seeing if Stroke Volume (or Stroke Distance) increases by more than 10%. If
the increase is more than 10%, repeat fluid boluses are administered until
such time as the increase is less than 10%: after this no further fluid is
given unless Stroke Volume falls by more than 10% - the process is designed to
achieve and maintain the individual patient's optimal Stroke Volume.
CardioQ-ODM is also used during surgery to guide administration of vaso-active
agents such as inotropes.

The CardioQ-ODM helps patients by enabling doctors to reduce the complications
that arise from  a medical  condition that is  common to  almost all  patients 
having surgery and many others in  intensive care or arriving in the  accident 
and emergency  department.  This  condition  is  known  as  hypovolaemia  -  a 
reduction in circulating blood volume -  and in surgical patients arises as  a 
direct consequence of  the combined effects  of pre-operative starvation,  the 
anaesthetic agents and the blood and fluid losses associated with the surgical
procedure itself. Hypovolaemia means that the body struggles to get sufficient
blood to  the tissues  and  vital organs  which  are consequently  starved  of 
essential oxygen. This  can cause medical  complications including  peripheral 
and major organ failure, which  if not dealt with  quickly can lead to  severe 
compromise or even death.

There are  already  over 2,500  CardioQ-ODMs  currently in  use  in  hospitals 
worldwide and distribution arrangements are in place in over 30 countries.  In 
addition, there are currently more than  250 clinical publications on the  use 
of the CardioQ-ODM which have repeatedly:-

·  Validated  the  results  of  CardioQ-ODM  against  known  standards  for 
measuring cardiac output

· Proved that CardioQ-ODM works in a wide range of surgical procedures

· Proved that CardioQ-ODM delivers 50% or more reductions in post-operative
complications and 25% or  more reductions in length  of hospital stay:  better 
care at lower cost.

The SupraQÔis an entirely non-invasive  device which uses an ultrasound  probe 
held at the  base of  the patient's neck  to track  the flow of  blood in  the 
aorta; it presents the same data as the CardioQ-ODM in a similar format and is
used for taking snapshots or monitoring over short periods.

                     This information is provided by RNS
           The company news service from the London Stock Exchange


MSCFEWFWEFESEES -0- Oct/23/2012 06:00 GMT
Press spacebar to pause and continue. Press esc to stop.